Armstrong Fleming & Moore’s AbbVie ABBV Stock Holding History

Armstrong Fleming & Moore’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$807K	Hold	3,207	–	–	0.27%	47
2026 Q1	$697K	Buy	3,207 +400	+14%	+$88.7K	0.3%	50
2025 Q4	$641K	Sell	2,807 -178	-6%	-$40.5K	0.3%	52
2025 Q3	$691K	Hold	2,985	–	–	0.33%	46
2025 Q2	$554K	Buy	2,985 +411	+16%	+$76.4K	0.3%	54
2025 Q1	$539K	Sell	2,574 -161	-6%	-$31.3K	0.65%	31
2024 Q4	$486K	Hold	2,735	–	–	0.29%	58
2024 Q3	$540K	Sell	2,735 -432	-14%	-$80.6K	0.31%	57
2024 Q2	$543K	Buy	3,167 +4	+0.1%	+$663	0.35%	51
2024 Q1	$576K	Buy	3,163 +4	+0.1%	+$689	0.4%	51
2023 Q4	$490K	Buy	3,159 +4	+0.1%	+$583	0.37%	52
2023 Q3	$470K	Sell	3,155 -46	-1%	-$6.75K	0.46%	50
2023 Q2	$431K	Buy	+3,201	New	+$469K	0.4%	55

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Armstrong Fleming & Moore's ABBV Position: Q2 2026 in Review

Armstrong Fleming & Moore held its AbbVie (ABBV) position steady in Q2 2026 at 3,207 shares worth $807K. The position accounts for 0.27% of the portfolio, ranked #47.

Armstrong Fleming & Moore first reported a position in ABBV in Q2 2023 and has held it in 13 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Armstrong Fleming & Moore held 3,207 shares of AbbVie worth $807K as of Q2 2026.
Armstrong Fleming & Moore left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.27% of Armstrong Fleming & Moore's portfolio in Q2 2026, its #47 holding.
Armstrong Fleming & Moore first reported a position in AbbVie in Q2 2023 and has held it in 13 quarters since.
4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Armstrong Fleming & Moore's 13F filing for Q2 2026, filed 28 Jul 2026.